DB:CNWK

Stock Analysis Report

Executive Summary

co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide.


Snowflake Analysis

High growth potential with mediocre balance sheet.

Share Price & News

How has co.don's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CNWK has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.9%

CNWK

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-40.2%

CNWK

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: CNWK underperformed the German Biotechs industry which returned 9% over the past year.

Return vs Market: CNWK underperformed the German Market which returned 14.4% over the past year.


Shareholder returns

CNWKIndustryMarket
7 Day-3.9%-2.3%-0.2%
30 Day8.4%-3.2%0.3%
90 Day7.5%6.3%3.7%
1 Year-38.8%-40.2%8.6%8.4%17.2%13.7%
3 Year-33.1%-34.7%44.5%42.9%15.4%5.3%
5 Year18.6%4.3%13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is co.don's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is co.don undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CNWK (€2.45) is trading below our estimate of fair value (€10.43)

Significantly Below Fair Value: CNWK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CNWK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CNWK is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CNWK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CNWK is overvalued based on its PB Ratio (4.4x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is co.don forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

69.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNWK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: CNWK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CNWK's is expected to become profitable in the next 3 years.

Revenue vs Market: CNWK's revenue (29.9% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: CNWK's revenue (29.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CNWK's Return on Equity is forecast to be low in 3 years time (0.4%).


Next Steps

Past Performance

How has co.don performed over the past 5 years?

-33.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CNWK is currently unprofitable.

Growing Profit Margin: CNWK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CNWK is unprofitable, and losses have increased over the past 5 years at a rate of -33.6% per year.

Accelerating Growth: Unable to compare CNWK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNWK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: CNWK has a negative Return on Equity (-90.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is co.don's financial position?


Financial Position Analysis

Short Term Liabilities: CNWK's short term assets (€9.1M) exceed its short term liabilities (€3.3M).

Long Term Liabilities: CNWK's short term assets (€9.1M) do not cover its long term liabilities (€9.9M).


Debt to Equity History and Analysis

Debt Level: CNWK is debt free.

Reducing Debt: CNWK has not had any debt for past 5 years.


Balance Sheet

Inventory Level: CNWK has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CNWK's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if CNWK has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CNWK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is co.don's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CNWK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CNWK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CNWK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNWK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CNWK's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average board tenure


CEO

co.don has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Tilmann Bur
Chairman of the Board & Additional Member of Executive Board0yrsno datano data
Thomas Krause
Member of the Supervisory Board7.4yrsno datano data
Hans-Joerg Bullinger
Member of Supervisory Board1.1yrsno datano data
Thommy Stählin
Member of the Supervisory Board14.3yrsno datano data
Hans Bauerfeind
Chairman of Supervisory Board2.2yrsno datano data
Beatrix Bauerfeind-Johnson
Member of Supervisory Board3.5yrsno datano data
Barbara Sickmüller
Member of the Supervisory Board9.6yrsno datano data

5.5yrs

Average Tenure

Experienced Board: CNWK's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.3%.


Top Shareholders

Company Information

co.don AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: co.don AG
  • Ticker: CNWK
  • Exchange: DB
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €61.225m
  • Shares outstanding: 24.30m
  • Website: https://www.codon.de

Number of Employees


Location

  • co.don AG
  • Warthestrasse 21
  • Teltow
  • Brandenburg
  • 14513
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNWKDB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 2001
CNWKXTRA (XETRA Trading Platform)YesCommon SharesDEEURFeb 2001
0Q37LSE (London Stock Exchange)YesCommon SharesGBEURFeb 2001
CNWKdBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURFeb 2001
CNWKETLX (Eurotlx)YesCommon SharesITEURFeb 2001

Biography

co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the minimally invasive repair of cartilage damage to knee joints following traumatic or degenerative defects. Its therapies include matrix-associated autologous cartilage transplantation, a biological therapy for the treatment of damaged articular cartilage with the body's own cells; and autologous chondrocyte transplantation for the regeneration of biomechanical load-bearing and pressure-resistant cartilage tissue. co.don AG was founded in 1993 and is headquartered in Teltow, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 20:44
End of Day Share Price2020/02/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.